BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
France Targets Shein, Temu With Fast-Fashion Fees 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Add as a preferred source on Google
Cancellation due to Travel Changes Caused by Inclement Weather
Management to Proceed with Scheduled Investor Meetings via Conference Calls
SOUTH SAN FRANCISCO, Calif., March 13, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the cancellation of the company’s presentation and webcast at the Cowen & Company 38th Annual Health Care Conference, previously scheduled to take place today, March 13th, at 8:00 AM Eastern Time at the Marriott Copley Place in Boston.
Management is no longer able to attend the conference as planned due to inclement weather in Boston. Willie Quinn, Chief Financial Officer, and Dayton Misfeldt, Interim Chief Executive Officer, will hold all scheduled investor meetings as phone calls. If you are an institutional investor with a scheduled meeting with Sunesis management, please proceed to your meeting room at the conference as planned, and reach out to [email protected] with any questions.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: | ||||||||||
| Maeve Conneighton | Willie Quinn | |||||||||
| Argot Partners | Sunesis Pharmaceuticals Inc. | |||||||||
| 212-600-1902 | 650-266-3716 | |||||||||
